首页 | 本学科首页   官方微博 | 高级检索  
     


Caprine mucopolysaccharidosis IIID
Authors:Margaret Z. Jones  Joseph Alroy  Erinn Downs-Kelly  Rebecca E. Lucas  Stacey A. Kraemer  Kevin T. Cavanagh  Barbara King  John J. Hopwood
Affiliation:(1) Division of Human Pathology, Colleges of Human and Osteopathic Medicine, Michigan State University, 48824 East Lansing, MI;(2) Department of Pathology, Schools of Medicine and Veterinary Medicine, Tufts University, 02111 Boston, MA;(3) Institute of Molecular Medicine and Genetics, Medical College of Georgia, 30912 Augusta, GA;(4) Michigan Department Community Health, Bureau of Laboratories, 48909 Lansing, MI;(5) Lysosomal Storage Diseases Unit, Department of Chemical Pathology, Women’s and Children’s Hospital, North Adelaide, South Australia
Abstract:Mucopolysaccharidosis IIID (MPS IIID) is a lysosomal storage disease associated with deficient activity of the enzyme N-acetylglucosamine 6-sulfatase (EC 3.1.6.14), a lysosomal hydrolase in the heparan sulfate glycosaminoglycan (HS-GAG) degradation pathway. In caprine MPS IIID, enzyme replacement therapy reversed early postnatal systemic but not primary or secondary central nervous system (CNS) substrate accumulations. The caprine MPS IIID large animal model system was used in this investigation to define the developmental profile of morphological and biochemical perturbations to estimate a time frame for therapeutic intervention. Light and electron microscopy were used to compare the CNS, liver, and kidney of normal +/+, MPS IIID carrier +/-, and MPS IIID-affected -/- goat kids (kids), at 60, 113–114, 128–129, and 135 d gestation (dg) of a 150-d gestational period, at birth, and at 59–64 d of postnatal (d-pn) age. In the CNS of -/- kids, morphological correlations of HS-GAG and glycolipid accumulations were evident in early differentiating neurons at 60 dg. CNS and systemic developmental, regional, and cellular differences in -/-kids at all time points included more prominent and earlier accumulation of lucent, putative HS-GAG substrates in lysosomes of meningeal and perivascular macrophages and hepatic sinusoidal cells than in CNS, hepatic, or renal parenchymal cells. The amounts and compositions of HS-GAG substrates in the brain and liver of +/+, +/-, and -/- kids were determined at 60, 65, 113–114, and 128–135 dg, at birth, and 53–78 d-pn. In the CNS of -/- kids, HS-GAG concentrations were variable and exceeded those of age-matched control tissue samples in the third but not the second trimester. In contrast, hepatic HS-GAG levels in -/- kids exceeded control values at all time points evaluated and paralleled the progressive morphological alterations. CNS and hepatic HS-GAG compositions in -/- kids were similar to each other and were more complex at all pre- and postnatal ages than those from control kids. Based on the time frame of development of CNS lesions and biochemical perturbations, prenatal therapeutic intervention in caprine MPS IIID is likely to be necessary to prevent or ameliorate substantive CNS and systemic lesions.
Keywords:Mucopolysaccharidosis IIID (MPS IIID)  Sanfilippo syndrome   N-acetylglucosamine 6-sulfatase  development  brain  CNS  liver  lysosomal storage diseases  heparan sulfate  glycosaminoglycans  glycolipids
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号